Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2

Fig. 3

Odds ratio of ≥ 50% MRR over Weeks 13‒24 in PROMISE-1 subgroups defined by baseline demographics and patient-reported outcome measures. CI, confidence interval; EQ-5D-5L, EuroQol 5-dimension, 5-level scale; MHDs, monthly headache days; MMDs, monthly migraine days; MRR, migraine responder rate; N/A, not applicable (sample size too small); OR, odds ratio; SF-36, 36-item Short-Form Health Survey

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us